Ultimately, sales of Nexletol and Nexlizet will be driven by insurer uptake, which in turn will depend on the net price after rebates, as well as an assessment of relative cost- and clinical effectiveness.
Market Prospects For New Cholesterol Lowering Agents Nexletol And Nexlizet
